• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


New Enrollment PAS Registry

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Adequate
Application Number P200039 / PAS001
Date Current Protocol Accepted  
Study Name New Enrollment PAS Registry
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source External Registry
Comparison Group No Control
Analysis Type Descriptive
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description The study is a prospective, multicenter, observational, single-arm post-approval study using new data collected in the National Cardiovascular Data Registry (NCDR) CathPCI Registry.
The objective of this study is to better understand the utilization, safety, and effectiveness of the Shockwave Coronary IVL System in a real-world setting.
Study Population Description Patients with severely calcified, stenotic de novo coronary artery lesions presenting with stable, unstable, or silent ischemia that are suitable for percutaneous coronary intervention (PCI) and with clinical characteristics similar to the Disrupt CAD III IDE study.
Sample Size Approximately 1000 patients in the CathPCI Registry including a minimum of 30 patients with permanent pacemakers [PPM] or implantable cardioverter defibrillators [ICDs].
Data Collection Safety endpoints:
Mortality and procedure-related adverse events IVL-specific data reporting
IVL-related ventricular arrhythmia
IVL balloon loss of pressure and related serious dissections
Safety of IVL in patients with PPM/ICD
Follow-up Visits and Length of Follow-up The timeline and milestones following approval of the protocol.

New Enrollment PAS Registry Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
6 month report 08/13/2021 08/11/2021 On Time
1 year report 02/12/2022 02/09/2022 On Time
18 month report 08/13/2022 08/04/2022 On Time
2 year report 02/12/2023    
3 year report 02/12/2024    

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources